DA-EPOCH-R highly active in Burkitt lymphoma with reduced toxicity vs high-intensity treatment regimens.
Fewer AEs and significantly longer PFS and ORR with ibrutinib vs temsirolimus.
Phase II data suggest that the chemotherapy-free regimen of ibrutinib plus rituximab is highly active in treatment-naive FL.
Ibrutinib is active in primary CNS lymphoma, achieving clinically meaningful CSF concentrations.
In this phase III trial that enrolled elderly treatment-naive patients with CLL, ibrutinib was associated with significant reductions in risk of progression and death vs chlorambucil.
In this phase II trial, R-bendamustine induction showed similar response rates, 2-year PFS, and 2-year OS with less hematologic and marrow toxicity vs R-hyperCVAD.
Use of interim PET allows more patients to avoid IFRT while still achieving 3-year PFS.
Phase I/II data suggest promise of combining brentuximab vedotin with ESHAP for patients with relapsed/refractory cHL who are transplantation candidates.
In this early study, pembrolizumab was highly active with durable responses in heavily pretreated patients with cHL who had failed brentuximab vedotin.
Alternate kinase inhibitor therapy following ibrutinib or idelalisib discontinuation can be efficacious.
Addition of 2 doses of bortezomib to frontline R-CHOP resulted in similar 2-year PFS rates in non-GCB DLBCL defined by the Hans IHC method.
Preliminary data show promising activity for the combination of venetoclax and rituximab, including an ORR of 86% and durable responses in the 55% of patients who achieved MRD negativity.
In this early-stage study, ACP-196 demonstrated promising activity in high-risk R/R CLL regardless of the presence of del(17p).
In this expert analysis, John M. Burke, MD, and Brad S. Kahl, MD, discuss the most clinically relevant data on the management of lymphomas presented at the 2015 American Society of Hematology annual meeting.
Combination idelalisib plus BR therapy significantly improved survival outcomes in patients with R/R CLL.
Single-agent venetoclax is active and achieved deep responses in relapsed/refractory CLL with del(17p).
In this downloadable slideset, John M. Burke, MD, and Brad S. Kahl, MD, review data from key studies in lymphoma presented at the 2015 American Society of Hematology Annual Meeting.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.